Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ProCanEx

Financiado

Cerrado

Prostate cancer diagnostic assay based on protein kinase activity profiling in e...

Prostate cancer diagnostic assay based on protein kinase activity profiling in exosomes The objective of the innovation project is the development of novel biomarker-based non-invasive assay for prostate cancer (PCa) detection. 417 000 Europeans were diagnosed with PCa in 2012, about 12% of all new cancer cases of Eu... ver más

30/11/2015

KINASERA

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

KINASERA OU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-11-30

PHC-12-2015-1: Clinical research for the validatio...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

KINASERA

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Nevada Diagnostics device for rapid testing of prostate cancer at P... 71K€ Cerrado

RTC-2017-6271-1 Desarrollo tecnológico para cuantificar en suero un nuevo ma... 405K€ Cerrado

PROSKit Prostate cancer urinary diagnostic kit based on RNA biomarke... 71K€ Cerrado

GlyCan Innovative Glycan based analysis for Cancer diagnostics 71K€ Cerrado

OCProDx Strategic planning for commercialisation of a multiplexed pr... 71K€ Cerrado

PROSTATOR Reliable urinary test for the diagnosis of prostate cancer 150K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2015-05-30
Fecha Fin: 2015-11-30

Líder del proyecto

KINASERA OU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The objective of the innovation project is the development of novel biomarker-based non-invasive assay for prostate cancer (PCa) detection. 417 000 Europeans were diagnosed with PCa in 2012, about 12% of all new cancer cases of European men. The diagnosis and screening of PCa totalled 12 billion USD in 2012 and will reach 17.4 billion USD in 2017 since the PSA test is performed for men over 50 years of age annually. The PCa diagnostics market is mainly covered by the Prostate-Specific Antigen (PSA) test, the practicality of which is debated. The low specificity of the test means a high number of false positives, leading to unnecessary and painful procedures (biopsies, treatment, etc.). More than 45 million PSA tests are performed annually worldwide, while more than 9 million of those are positive, with around 70% false positives. Our assay is built on an innovative technological platform based on quantitative profiling of protein kinases in circulating exosomes. Recent scientific literature supports the potential of exosomes as diagnostic markers. Our assay combines two innovative approaches - newly discovered changes in exosome composition in cancer and probes for measuring altered levels of several protein kinases in exosomes originating from the cancer tissue. We will use the phase I of the SME instrument to make a detailed business plan, market research and evaluate technological, technical and practical issues. Collaboration with a potential licensee and complementary sources of financing for Phase II are sought. A detailed research plan will be conducted. Cancer diagnostics is among the main concerns for healthcare as cancer is among the deadliest diseases. Our proposal aims at development of innovative, non-invasive, highly reliable and cost-effective test for PCa, which would contribute to the sustainability of European health care system. Our strategy will enable patient stratification and/or prognosis of disease leading to the improved clinical decisions.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores